Pharmaceuticals

Global Male Hypogonadism Market Expected To Reach $1.38 Billion By 2030 With 9.2% CAGR

May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Male Hypogonadism Market In 2026, And How Will Its Value Evolve By 2030?

The male hypogonadism market size has demonstrated robust growth in recent years. It is anticipated to expand from $3.95 billion in 2025 to $4.17 billion in 2026, at a compound annual growth rate (CAGR) of 5.6%. This historical increase can be attributed to the rising prevalence of hypogonadism, increased awareness regarding testosterone deficiency, the growing aging male population, continuous advancements in hormone replacement therapies, and a greater adoption of diagnostic testing by physicians.

The male hypogonadism market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $5.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.4%. This anticipated growth during the forecast period stems from factors such as the broadening of personalized medicine, the incorporation of AI into diagnosis and treatment, an increase in telehealth services, the growing embrace of advanced drug delivery systems, and enhanced investment in male hormonal research. Key developments expected during this period encompass personalized testosterone therapy, the development of minimally invasive drug delivery systems, initiatives for male hormonal health awareness, the incorporation of telemedicine into hormonal treatment, and the widening of chronic disease management services.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9969&type=smp

What Factors Are Contributing To The Growth Of The Male Hypogonadism Market?

The escalating infertility rates are anticipated to propel the growth of the male hypogonadism market in the future. Infertility is defined as a condition impacting the male or female reproductive system, characterized by the inability to achieve pregnancy after a minimum of 12 months of consistent, unprotected sexual activity. Male hypogonadism, which can result in diminished sperm production and infertility, is recognized as a potential contributor to male infertility. Consequently, the rising incidence of male infertility is projected to drive the growth of the male hypogonadism market. For instance, in February 2023, the Office for National Statistics, a UK-based government department, reported that 31.8% of all live births in England and Wales were to non-UK-born mothers, an increase from 30.3% in 2022. Additionally, 37.3% of live births had at least one parent born outside the UK, up from 35.8% in 2022. Therefore, an increase in the infertility rate is driving the growth of the male hypogonadism market.

What Are The Different Segment Types In The Male Hypogonadism Market Segment Breakdown?

The male hypogonadism market covered in this report is segmented –

1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types

2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries

3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy

Subsegments:

1) By Klinefelter’s Syndrome: 47,XXY Syndrome, Other Variants

2) By Kallmann Syndrome: Isolated Kallmann Syndrome, Syndromic Kallmann Syndrome

3) By Pituitary Disorders: Hypopituitarism, Pituitary Tumors, Other Pituitary Disorders

4) By Other Types: Androgen Insensitivity Syndrome, Testicular Dysgenesis Syndrome, Genetic Mutations And Disorders

What Trends Are Shaping The Future Of The Male Hypogonadism Market?

Leading companies active in the male hypogonadism market are dedicating efforts to creating innovative products, such as digital-first platforms. These platforms aim to engage patients through telemedicine, provide educational resources, and streamline access to treatments, thereby transforming care for male hypogonadism while enhancing patient support and ease of therapy access. As an illustration, in October 2024, LifeMD, Inc., a US-based provider of virtual primary care services, launched TestoRx, a direct-to-consumer telehealth service for testosterone replacement therapy, offered under its Rex MD men’s health brand. This program encompasses an initial virtual consultation and requisite blood testing, treatment choices including both testosterone replacement and alternative therapies to boost endogenous hormone production, and ongoing telehealth visits with follow-up care.

Who Are The Well-Known Companies In The Male Hypogonadism Market?

Major companies operating in the male hypogonadism market are Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Antares Pharma Inc., Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, TherapeuticsMD Inc., Viking Therapeutics Inc., Shionogi & Co. Ltd., Ferring Pharmaceuticals

Get The Full Male Hypogonadism Market Report:

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

Which Region Holds The Highest Market Share In The Male Hypogonadism Market?

North America was the largest region in the male hypogonadism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Male Hypogonadism Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

Browse Through More Reports Similar to the Global Male Hypogonadism Market 2026, By The Business Research Company

Male Hypogonadism Market Report 2026

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

Male Fertility Market Report 2026

https://www.thebusinessresearchcompany.com/report/male-fertility-global-market-report

Human Chorionic Gonadotropin Market Report 2026

https://www.thebusinessresearchcompany.com/report/human-chorionic-gonadotropin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795